Loading
Dutch radiation oncologist who was lead author of PORTEC-2, the trial that showed vaginal brachytherapy is as good as pelvic radiotherapy for high-intermediate-risk endometrial cancer, with fewer side effects.
Remi Nout is a radiation oncologist who trained in the Leiden PORTEC group and now leads radiation oncology at Erasmus MC in Rotterdam. He was first author of the 2010 Lancet report of PORTEC-2, in which vaginal brachytherapy gave vaginal recurrence control equivalent to external-beam pelvic radiotherapy in high-intermediate-risk endometrial cancer with less bowel toxicity and better quality of life, making brachytherapy the standard adjuvant treatment for this group. He also leads international trials in cervical cancer radiotherapy.
| Title | Journal | Year |
|---|---|---|
| PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer | The Lancet | 2010 |
Shares Endometrial cancer and the tags endometrial, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares Endometrial cancer and the tags endometrial, radiotherapy.
Shares Endometrial cancer, Cervical cancer and the tags endometrial, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares the tags radiotherapy, trialist.
Shares the tags radiotherapy, trialist.